Pluvicto (lutetium Lu 177 vipivotide tetraxetan): What It Is and Trial History

Evidence tier: Established (FDA-approved; multiple randomized controlled trials).

This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication. It summarises what the peer-reviewed literature and regulatory approval documents have reported about Pluvicto, and it does not tell anyone what to do about treatment.

What Pluvicto Is

Pluvicto is the brand name used by Novartis for lutetium Lu 177 vipivotide tetraxetan, also written in the scientific literature as [¹⁷⁷Lu]Lu-PSMA-617. It belongs to a drug class called radioligand therapy (sometimes called targeted radionuclide therapy or theranostics), in which a small targeting molecule is chemically linked to a radioactive isotope so that radiation is delivered preferentially to cells carrying a particular surface marker.

The molecule has three parts. A urea-based ligand binds prostate-specific membrane antigen (PSMA), a transmembrane protein that is expressed at high levels on most prostate adenocarcinoma cells and at far lower levels on most normal tissue. A linker connects that ligand to tetraxetan (DOTA), a chelator that holds a metal atom. The metal in this case is lutetium-177, a beta-emitting radionuclide. A 2022 review described the compound as the first radiopharmaceutical of this type approved by the FDA for the treatment of prostate cancer (PMID 36297404).

How the mechanism has been described

Published descriptions of the mechanism follow a consistent sequence: after intravenous administration, the ligand circulates and binds PSMA on tumour cells; the complex is internalised; and the lutetium-177 atom emits beta particles that damage DNA in the bound cell and in nearby cells within a short tissue range. A review of the compound's development explained that this PSMA-directed delivery is what distinguishes it from systemic cytotoxic chemotherapy, and that PSMA expression on the tumour must be demonstrated by imaging before treatment (PMID 36811416). Because lutetium-177 also emits a small amount of gamma radiation, the same reviewers noted that its distribution in the body can be visualised on post-treatment scans (PMID 36297404).

Approved Indication and Approval Timeline

A published FDA approval summary reported that lutetium Lu 177 vipivotide tetraxetan was approved in March 2022 for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had previously been treated with androgen receptor pathway inhibition and taxane-based chemotherapy (PMID 36469000). A separate first-approval report published the same year described the same 2022 US approval and the drug's development as a PSMA-targeted radioligand therapy for mCRPC (PMID 35553387).

Eligibility in the approval literature was tied to PSMA positivity established by PSMA-targeted positron emission tomography imaging, meaning the indication is defined not only by tumour type and prior therapy but also by a biomarker demonstrated on a scan (PMID 36469000). Reviews of the product have emphasised that this pairing of a diagnostic scan with a matched therapeutic agent is the defining feature of the theranostic approach (PMID 36305305).

Trial History: The Pivotal Evidence as Published

The registration trial

The FDA approval summary reported that approval rested on a randomised, open-label trial in men with PSMA-positive mCRPC who had already received an androgen receptor pathway inhibitor and taxane chemotherapy, in which participants were assigned to receive the radioligand together with best standard of care or to standard of care alone (PMID 36469000). The trial used two main endpoints: overall survival and radiographic progression-free survival.

According to that approval summary, median overall survival was 15.3 months in the arm receiving the radioligand plus standard of care compared with 11.3 months with standard of care alone, and median radiographic progression-free survival was 8.7 months versus 3.4 months (PMID 36469000). Reviews published after the approval summarised these results as the basis for the drug's place in later-line mCRPC treatment (PMID 36811416).

The wider trial literature

Beyond the registration trial, a 2023 systematic review examined published studies of lutetium-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer and summarised reported efficacy and toxicity outcomes across the identified trials and cohorts (PMID 37194261). A literature review published in a pharmacy practice journal similarly compiled the accumulated clinical data on lutetium Lu 177 vipivotide tetraxetan, including its pharmacology, administration setting and reported outcomes (PMID 41217772).

Readers evaluating this literature should note the design limits researchers have described: the registration trial was open-label rather than blinded, the comparator was investigator-chosen standard of care, and participants were selected on the basis of PSMA imaging, so the reported outcomes apply to a biomarker-selected population rather than to all men with advanced prostate cancer (PMID 36469000).

The Regimen as Approved and Studied

Doses below are described only as they appear in the published approval literature. They are not guidance, and decisions about whether any regimen is appropriate belong to a patient and their prescriber.

The FDA approval summary reported an intravenous regimen of 7.4 GBq (200 mCi) administered every 6 weeks for up to 6 doses (PMID 36469000). The first-approval report described the same intravenous radioligand regimen used in the mCRPC setting (PMID 35553387). Reviews have noted that administration occurs in facilities licensed to handle radioactive drugs, with radiation-safety precautions for patients, caregivers and staff after each dose (PMID 36297404).

Adverse Events: What Studies Report

Adverse events are summarised here as researchers and regulators reported them. Individual experience varies, and any symptom during or after treatment is a matter for the treating team.

Events reported in the registration trial

The FDA approval summary reported that the most common adverse reactions in the pivotal trial included fatigue, dry mouth, nausea, anaemia, decreased appetite and constipation (PMID 36469000). Reviews of the product have described dry mouth (xerostomia) as an expected consequence of PSMA expression in salivary glands, which allows some of the radioligand to accumulate there (PMID 36811416).

Organ-system toxicities described across lutetium-177 therapies

A 2023 review of the safety and therapeutic optimisation of lutetium-177-based radiopharmaceuticals examined the toxicities that recur across this drug class, including effects on the bone marrow, kidneys and salivary glands, and discussed dosimetry and administration strategies studied to limit exposure to those organs (PMID 37111725). Reviews of lutetium Lu 177 vipivotide tetraxetan specifically have highlighted myelosuppression — reductions in red cells, white cells and platelets — as the toxicity most often prompting laboratory monitoring between doses (PMID 36305305).

Rarer events described in case reports

A 2024 case report described diffuse pneumonitis occurring after lutetium-177-PSMA-617 treatment in a patient with metastatic castration-resistant prostate cancer (PMID 38395466). A single case report cannot establish how often such an event occurs or whether the drug caused it, but the authors documented it as a possible pulmonary complication warranting awareness.

Post-marketing signal analysis

A 2025 disproportionality analysis of the FDA Adverse Event Reporting System catalogued adverse events reported in association with lutetium-177-PSMA-617 in advanced prostate cancer and assessed which events were reported more often than expected relative to other drugs in the database (PMID 41029272). Spontaneous reporting databases are subject to under-reporting, duplicate reports and confounding by the underlying illness, so the researchers' findings describe reporting patterns rather than confirmed causal relationships (PMID 41029272).

Regulatory Status and Practical Context

Pluvicto is a prescription radiopharmaceutical approved by the FDA in March 2022 and available only through licensed nuclear medicine or radiation oncology facilities, as described in the approval literature (PMID 36469000). Because the product is radioactive, its handling, storage, administration and waste disposal are governed by radiation-safety regulations in addition to ordinary drug regulations, a point reviews have repeatedly emphasised when describing the infrastructure needed to deliver radioligand therapy (PMID 36297404).

Two regulatory facts follow from that. First, there is no compounded version of this medicine: the product is manufactured under radiopharmaceutical conditions with a decaying isotope and a limited usable shelf life, and it is not the type of drug that compounding pharmacies prepare. Second, treatment scheduling depends on isotope production and shipping logistics, so appointment timing is set by the treating centre rather than by patient preference. Supply and scheduling questions are handled by the treating institution and the manufacturer, and any specific availability information should come from those sources rather than from a general education page.

Warnings and precautions described in reviews of the product centre on radiation exposure to patients and contacts, myelosuppression, renal effects and the potential for impaired fertility, alongside routine laboratory monitoring during the treatment course (PMID 36305305). The published approval summary and product reviews should be read alongside the current manufacturer labeling, which is the authoritative source for prescribing information (PMID 36469000).

How Pluvicto Differs From Related PSMA-617 Products

The targeting molecule, PSMA-617, is not unique to Pluvicto; what defines the product is the specific radionuclide attached to it. A 2026 radiochemistry study compared PSMA-617 labeled with lead-212, actinium-225 and lutetium-177, assessing the radiolabeling chemistry and in vitro behaviour of each construct (PMID 42159963). Lead-212 and actinium-225 are alpha emitters, which deposit energy over a much shorter range than the beta particles emitted by lutetium-177; those alpha-labeled constructs are investigational and are not the approved product (PMID 42159963).

A second distinction is between therapeutic and diagnostic PSMA agents. Patient selection for the approved therapy depends on a PSMA-targeted PET scan performed with a separate imaging radiopharmaceutical, not with Pluvicto itself, as the approval summary described (PMID 36469000). A third distinction is between PSMA ligands: the systematic review of lutetium-177 PSMA therapy noted that more than one PSMA-binding ligand has been studied clinically, so published data on lutetium-177 PSMA therapy in general do not all refer to the specific approved formulation (PMID 37194261).

Questions a Prescriber Can Answer

Because the approved indication is narrow and biomarker-defined, most practical questions about this medicine are individual rather than general. Topics that oncologists, nuclear medicine physicians and pharmacists routinely address include:

• Whether prior therapy history matches the approved indication described in the approval summary (PMID 36469000).
• What a PSMA PET scan showed and how PSMA positivity was determined (PMID 36469000).
• What blood-count and kidney-function monitoring is planned between doses, given the myelosuppression and renal effects described across lutetium-177 therapies (PMID 37111725).
• What radiation-safety precautions apply after each administration (PMID 36297404).
• How reported adverse events such as dry mouth, fatigue and anaemia are managed if they occur (PMID 36469000).

Key Takeaways

• Pluvicto is Novartis's brand of lutetium Lu 177 vipivotide tetraxetan, described in the literature as the first FDA-approved radiopharmaceutical of its kind for prostate cancer (PMID 36297404).
• The FDA approved it in March 2022 for PSMA-positive mCRPC after androgen receptor pathway inhibition and taxane chemotherapy (PMID 36469000).
• The registration trial reported median overall survival of 15.3 versus 11.3 months and radiographic progression-free survival of 8.7 versus 3.4 months (PMID 36469000).
• Commonly reported adverse reactions included fatigue, dry mouth, nausea, anaemia, decreased appetite and constipation (PMID 36469000), with marrow, kidney and salivary-gland toxicity discussed across the lutetium-177 class (PMID 37111725).
• Post-marketing reporting data have been analysed for additional signals, but such analyses describe reporting patterns rather than proven causation (PMID 41029272).

PeptideU is not affiliated with or endorsed by Novartis. Pluvicto is a trademark of its owner. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

References

• [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer (Pharmaceuticals, 2022)
• FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer (Clinical Cancer Research, 2023)
• Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review (Expert Review of Anticancer Therapy, 2023)
• Lutetium Lu 177 Vipivotide Tetraxetan: First Approval (Molecular Diagnosis & Therapy, 2022)
• Lutetium Lu 177 vipivotide tetraxetan for prostate cancer (Drugs of Today, 2023)
• Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer (Expert Review of Anticancer Therapy, 2022)
• Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals (Pharmaceutics, 2023)
• Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer (BMJ Case Reports, 2024)
• Lutetium Lu 177 vipivotide tetraxetan: A literature review (Journal of Oncology Pharmacy Practice, 2026)
• Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto) in advanced prostate cancer: a disproportionality analysis based on the FDA's Adverse Event Reporting System (FAERS) (BMC Cancer, 2025)
• Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212, actinium-225, and lutetium-177 (EJNMMI Radiopharmacy and Chemistry, 2026)